EUVIMEDEUVIMED entdecken
Crossref

Limited progress in clinical trials for rare urologic cancers

Etan Eigner, Nicola Fazaa, Ameer Nsair, Melissa Atallah, Jathin Bandari, Gilad E Amiel, Azik Hoffman, Kamil Malshy

Canadian Urological Association Journal · 20.08.2026 · 20 (12)

DOI: 10.5489/cuaj.9671 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Urological Association Journal, online erschienen am 20.08.2026. Verfasst von Etan Eigner und 7 weiteren Autor:innen. Beteiligte Einrichtung: Rappaport Faculty of Medicine, Technion Haifa, Israel.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

We aimed to characterize the contemporary landscape, completion rates, and predictors of completion of clinical trials in testicular and penile cancers.

Methods

We performed a registry-based cohort analysis of ClinicalTrials.gov to identify interventional and observational trials in testicular or penile cancer initiated between January 1, 2000, and October 1, 2025. Trials withdrawn before enrollment, supportive-care or non-oncologic studies, epidemiologic investigations, and basket trials without predefined disease-specific enrollment targets were excluded. Extracted variables included trial design, enrollment targets, funding source, geographic region, and completion status. Firth’s penalized logistic regression was used to assess predictors of trial completion. Kaplan-Meier and Cox proportional hazards models evaluated time to trial completion.

Results

Eighty-three eligible trials were identified, including 34 penile and 49 testicular cancer studies. Most trials were early-phase, non-randomized, and small. Overall completion rates were low (38% for penile cancer and 41% for testicular cancer), with no significant difference by disease site. Trials conducted outside North America were significantly more likely to complete than North American studies (adjusted odds ratio 10.21; 95% confidence interval [CI] 2.11–68.27). Time-to-event analyses similarly demonstrated faster completion among non-North American trials (multivariable hazard ratio 5.02, 95% CI 1.84–13.66).

Conclusions

Clinical trials in rare urologic cancers demonstrate persistently low completion rates and substantial geographic disparities, highlighting the need for improved international collaboration and alternative trial frameworks to enhance trial feasibility and completion.

Autor:innen und Institutionen

  • Rappaport Faculty of Medicine, Technion Haifa, Israel.
  • The Department of Urology, Rambam Health Care Campus, Haifa, Israel.
  • Department of Urology, University of Rochester Medical Center, Rochester, NY, United States.

Zitieren

APA

Eigner, E., Fazaa, N., Nsair, A., Atallah, M., Bandari, J., Amiel, G. E., Hoffman, A., & Malshy, K. (2026). Limited progress in clinical trials for rare urologic cancers. Canadian Urological Association Journal, 20(12). https://doi.org/10.5489/cuaj.9671

Vancouver

Eigner E, Fazaa N, Nsair A, Atallah M, Bandari J, Amiel GE, et al. Limited progress in clinical trials for rare urologic cancers. Canadian Urological Association Journal. 2026;20(12). doi:10.5489/cuaj.9671

BibTeX
@article{Eigner2026,
  author = {Eigner, Etan and Fazaa, Nicola and Nsair, Ameer and Atallah, Melissa and Bandari, Jathin and Amiel, Gilad E and Hoffman, Azik and Malshy, Kamil},
  title = {Limited progress in clinical trials for rare urologic cancers},
  journal = {Canadian Urological Association Journal},
  year = {2026},
  volume = {20},
  number = {12},
  doi = {10.5489/cuaj.9671}
}
Kostenlos starten →